Search clinical trials for: JS001(Toripalimab) JS002

Total 444 results

LaNova Medicines Limited

Terminated

Study of LM-061 in Subjects in Advanced Tumors

Advanced Tumours

Australia
Sun Yat-sen University

Unknown

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery (SNMM)

Malignant Melanoma | Sinonasal Melanoma

China
Zogenix, Inc.

Completed

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Chronic Pain

United States
Tianjin Medical University General Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Cervical Cancer | Cervix Cancer | Cervix Neoplasm

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

Non-small Cell Lung Cancer | Second-line Treatment

China
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody Improve Mixed Chimerism (HLH)

PD-1 Antibody | Mixed Chimerism

China
The Central Hospital of Lishui City

Not yet recruiting

Immunotherapy After Radiotherapy in Elderly ESCC (TREE)

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Second Affiliated Hospital, School of Medicine,...

Recruiting

Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Colorectal Cancer

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Tianjin Medical University Cancer Institute and...

Recruiting

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Cervical Cancer | Immunotherapy | Induction Chemotherapy

China
Hebei Medical University Fourth Hospital

Recruiting

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer (Best-EEC)

Esophageal Carcinoma

China
Fudan University

Recruiting

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (SLOT)

Microsatellite Stable Metastatic Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Cervical Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Recurrent Nasopharyngeal Squamous Cell Carcinoma | Toripalimab

China
Henan Cancer Hospital

Recruiting

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Chemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric Carcinoma

China
Sun Yat-sen University

Recruiting

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Solid Tumor | Advanced Cancer

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Advanced Solid Tumor

China
Sichuan University

Recruiting

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Advanced Solid Tumor

China
Ruijin Hospital

Recruiting

Toripalimab Combined With Definitive CCRT for LACC Patients

Cervical Cancer | Immunotherapy | Chemoradiotherapy

China
Sun Yat-sen University

Enrolling by invitation

PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients

Anal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage I | Anal Canal Cancer Stage II | Anal Canal Cancer Stage III

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

Melanoma

China
Shanghai Zhongshan Hospital
Shanghai Junshi Bioscience Co., Ltd.; OrigiMed

Completed

A Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): (SCORPIO)

Gastroesophageal Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University

Recruiting

Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Cancer

China
RenJi Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Advanced Esophageal Squamous Cell Cancer

China
Eye & ENT Hospital of Fudan University

Recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

China
Sun Yat-sen University
The First Hospital of Nanchang

Not yet recruiting

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Zhejiang University

Recruiting

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Colorectal Cancer

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Fudan University
Shanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaborators

Recruiting

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Hypopharyngeal Cancer | Larynx Cancer

China
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Zhujiang Hospital

Recruiting

RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Toripalimab Combined With SBRT for NSCLC

Non-small Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Mismatch Repair Deficiency | Adenocarcinoma of Esophagogastric Junction

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Yu jiren

Not yet recruiting

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Epstein-Barr Virus-Associated Gastric Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Thymic Epithelial Tumor

China
West China Hospital

Recruiting

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Rectal Cancer

China

Search clinical trials for: JS001(Toripalimab) JS002

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations